The small biotech company Pharmacyclics was on the ropes, teetering toward bankruptcy. Its one big product had flopped. Its top chemist, co-founders and entire board of directors resigned, frustrated and disappointed. Its new CEO knew almost nothing about biotech. And then the recession hit.
All it had left was a single chemical, bought for chump change because no one else wanted it.
